ProPhase Labs, Inc. (PRPH)
USD 0.33
(2.45%)
USD 0.33
(2.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.82 Million USD | -151.77% |
| 2022 | 28.73 Million USD | 105.69% |
| 2021 | 11.38 Million USD | 504.21% |
| 2020 | -1.48 Million USD | -21.96% |
| 2019 | -2.7 Million USD | -73.87% |
| 2018 | -1.25 Million USD | 54.72% |
| 2017 | -3.67 Million USD | -61.91% |
| 2016 | -3.44 Million USD | 37.81% |
| 2015 | -1.79 Million USD | 15.61% |
| 2014 | -7.55 Million USD | -742.51% |
| 2013 | 648 Thousand USD | 121.01% |
| 2012 | -839 Thousand USD | -32.02% |
| 2011 | -2.35 Million USD | 26.25% |
| 2010 | -3.17 Million USD | 18.08% |
| 2009 | -3.4 Million USD | 34.12% |
| 2008 | -5.66 Million USD | -167.25% |
| 2007 | -1.46 Million USD | -110.38% |
| 2006 | 162.88 Thousand USD | -124.29% |
| 2005 | 4.38 Million USD | 621.82% |
| 2004 | 1.1 Million USD | -45.25% |
| 2003 | 1.1 Million USD | 122.75% |
| 2002 | -4.87 Million USD | -7688.8% |
| 2001 | 64.24 Thousand USD | 101.15% |
| 2000 | -5.35 Million USD | 27.66% |
| 1999 | -6.78 Million USD | -190.59% |
| 1998 | 9.85 Million USD | -75.99% |
| 1997 | 35.4 Million USD | 5157.14% |
| 1996 | -700 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -6.09 Million USD | 6.93% |
| 2024 Q1 | -6.5 Million USD | 29.38% |
| 2023 Q1 | 2.15 Million USD | 153.3% |
| 2023 Q4 | -9.41 Million USD | -104.39% |
| 2023 FY | - USD | -151.77% |
| 2023 Q3 | -4.6 Million USD | -46.5% |
| 2023 Q2 | -3.14 Million USD | -245.83% |
| 2022 FY | - USD | 105.69% |
| 2022 Q4 | -4.04 Million USD | -221.11% |
| 2022 Q3 | 3.34 Million USD | -72.08% |
| 2022 Q2 | 11.96 Million USD | -31.83% |
| 2022 Q1 | 17.55 Million USD | 13.31% |
| 2021 Q4 | 15.49 Million USD | 751.94% |
| 2021 FY | - USD | 504.21% |
| 2021 Q2 | -572 Thousand USD | -129.65% |
| 2021 Q1 | 1.92 Million USD | 481.23% |
| 2021 Q3 | -2.37 Million USD | -315.38% |
| 2020 Q4 | -506 Thousand USD | 10.76% |
| 2020 Q1 | -730 Thousand USD | -97.3% |
| 2020 Q3 | -567 Thousand USD | -493.75% |
| 2020 Q2 | 144 Thousand USD | 119.73% |
| 2020 FY | - USD | -21.96% |
| 2019 Q4 | -370 Thousand USD | -2.49% |
| 2019 FY | - USD | -73.87% |
| 2019 Q3 | -361 Thousand USD | 69.07% |
| 2019 Q2 | -1.16 Million USD | -11.78% |
| 2019 Q1 | -1.04 Million USD | -236.77% |
| 2018 Q2 | -169 Thousand USD | -502.38% |
| 2018 FY | - USD | 54.72% |
| 2018 Q1 | 42 Thousand USD | -14.29% |
| 2018 Q3 | -815 Thousand USD | -382.25% |
| 2018 Q4 | -310 Thousand USD | 61.96% |
| 2017 Q3 | -806 Thousand USD | 46.8% |
| 2017 Q2 | -1.51 Million USD | -84.53% |
| 2017 Q4 | 49 Thousand USD | 106.08% |
| 2017 Q1 | -821 Thousand USD | -101.23% |
| 2017 FY | - USD | -61.91% |
| 2016 Q3 | 324 Thousand USD | 133.47% |
| 2016 Q2 | -968 Thousand USD | 24.61% |
| 2016 Q4 | -408 Thousand USD | -225.93% |
| 2016 Q1 | -1.28 Million USD | -3.3% |
| 2016 FY | - USD | 37.81% |
| 2015 Q4 | -1.24 Million USD | -278.59% |
| 2015 Q3 | 696 Thousand USD | 146.96% |
| 2015 Q1 | -1.29 Million USD | -92.28% |
| 2015 FY | - USD | 15.61% |
| 2015 Q2 | -1.48 Million USD | -14.35% |
| 2014 FY | - USD | -742.51% |
| 2014 Q1 | -738 Thousand USD | -208.85% |
| 2014 Q2 | -3.06 Million USD | -315.58% |
| 2014 Q3 | 432 Thousand USD | 114.09% |
| 2014 Q4 | -674 Thousand USD | -256.02% |
| 2013 Q3 | 1.29 Million USD | 177.86% |
| 2013 Q2 | -1.66 Million USD | -673.1% |
| 2013 Q1 | 290 Thousand USD | 118.17% |
| 2013 FY | - USD | 121.01% |
| 2013 Q4 | 678 Thousand USD | -47.6% |
| 2012 Q3 | 1.14 Million USD | 161.0% |
| 2012 Q1 | -632 Thousand USD | 64.43% |
| 2012 Q4 | -1.59 Million USD | -240.0% |
| 2012 Q2 | -1.86 Million USD | -195.73% |
| 2012 FY | - USD | -32.02% |
| 2011 Q3 | 1.2 Million USD | 236.46% |
| 2011 Q1 | -928 Thousand USD | 14.47% |
| 2011 Q2 | -886 Thousand USD | 4.53% |
| 2011 FY | - USD | 26.25% |
| 2011 Q4 | -1.77 Million USD | -246.98% |
| 2010 Q1 | -982 Thousand USD | -154.37% |
| 2010 Q3 | 1.03 Million USD | 147.1% |
| 2010 FY | - USD | 18.08% |
| 2010 Q4 | -1.08 Million USD | -205.03% |
| 2010 Q2 | -2.19 Million USD | -123.32% |
| 2009 Q2 | -4.62 Million USD | -109.45% |
| 2009 FY | - USD | 34.12% |
| 2009 Q1 | -2.21 Million USD | -10.53% |
| 2009 Q4 | 1.8 Million USD | 37.96% |
| 2009 Q3 | 1.3 Million USD | 128.28% |
| 2008 Q4 | -1.99 Million USD | -345.64% |
| 2008 Q3 | 814.04 Thousand USD | 127.47% |
| 2008 Q1 | -2.58 Million USD | -270.79% |
| 2008 Q2 | -2.96 Million USD | -14.79% |
| 2008 FY | - USD | -167.25% |
| 2007 Q3 | 1.15 Million USD | 130.35% |
| 2007 FY | - USD | -110.38% |
| 2007 Q1 | -2.08 Million USD | -297.28% |
| 2007 Q2 | -3.81 Million USD | -82.81% |
| 2007 Q4 | 1.51 Million USD | 30.46% |
| 2006 Q3 | 889.67 Thousand USD | 132.62% |
| 2006 FY | - USD | -124.29% |
| 2006 Q4 | 1.05 Million USD | 18.98% |
| 2006 Q2 | -2.72 Million USD | -69.12% |
| 2006 Q1 | -1.61 Million USD | -176.03% |
| 2005 Q1 | -194.93 Thousand USD | -109.84% |
| 2005 Q2 | -1.86 Million USD | -854.39% |
| 2005 FY | - USD | 621.82% |
| 2005 Q3 | 2.91 Million USD | 256.62% |
| 2005 Q4 | 2.12 Million USD | -27.21% |
| 2004 Q3 | -263.48 Thousand USD | 71.12% |
| 2004 Q1 | -800.32 Thousand USD | -131.68% |
| 2004 Q2 | -912.47 Thousand USD | -14.01% |
| 2004 Q4 | 1.98 Million USD | 852.21% |
| 2004 FY | - USD | -45.25% |
| 2003 Q4 | 2.52 Million USD | 2093.21% |
| 2003 Q2 | -1.08 Million USD | -17.57% |
| 2003 Q3 | 115.2 Thousand USD | 110.63% |
| 2003 FY | - USD | 122.75% |
| 2003 Q1 | -922.1 Thousand USD | 38.88% |
| 2002 Q2 | -1.48 Million USD | 14.77% |
| 2002 Q4 | -1.5 Million USD | -178.22% |
| 2002 Q3 | -330.71 Thousand USD | 63.55% |
| 2002 Q1 | -1.74 Million USD | -298.59% |
| 2002 FY | - USD | -7688.8% |
| 2001 Q3 | 121.59 Thousand USD | 103.56% |
| 2001 FY | - USD | 101.15% |
| 2001 Q1 | -555.2 Thousand USD | -1652.36% |
| 2001 Q2 | -2.14 Million USD | -515.83% |
| 2001 Q4 | 878.98 Thousand USD | 622.88% |
| 2000 Q4 | 35.76 Thousand USD | 157.61% |
| 2000 FY | - USD | 27.66% |
| 2000 Q3 | -62.08 Thousand USD | 96.57% |
| 2000 Q2 | -1.81 Million USD | 55.84% |
| 2000 Q1 | -4.09 Million USD | -173.24% |
| 1999 FY | - USD | -190.59% |
| 1999 Q1 | -3.46 Million USD | -208.33% |
| 1999 Q2 | -2 Million USD | 48.72% |
| 1999 Q3 | -200 Thousand USD | 90.0% |
| 1999 Q4 | -1.5 Million USD | -650.0% |
| 1998 Q4 | 3.9 Million USD | -12.2% |
| 1998 Q1 | 1.7 Million USD | -91.45% |
| 1998 Q3 | 4.5 Million USD | 1125.0% |
| 1998 FY | - USD | -75.99% |
| 1998 Q2 | -400 Thousand USD | -130.77% |
| 1997 Q1 | 10.9 Million USD | 461.86% |
| 1997 Q4 | 15.2 Million USD | 105.41% |
| 1997 Q2 | 1.8 Million USD | -83.49% |
| 1997 FY | - USD | 5157.14% |
| 1997 Q3 | 7.4 Million USD | 311.11% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | 1.94 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 90.122% |
| Theratechnologies Inc. | -10.31 Million USD | -43.773% |
| Safety Shot Inc | -12.18 Million USD | -21.681% |
| Cosmos Health Inc. | -17.06 Million USD | 13.098% |
| Cronos Group Inc. | -72.14 Million USD | 79.449% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 98.397% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 58.907% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 141.151% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -361.172% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -227.669% |
| Dynavax Technologies Corporation | 9.66 Million USD | 253.393% |
| Radius Health, Inc. | 38.31 Million USD | 138.703% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -530.665% |
| Alvotech | -484.86 Million USD | 96.942% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -287.693% |
| Alpha Teknova, Inc. | -25.53 Million USD | 41.944% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 90.666% |
| SCYNEXIS, Inc. | 73.47 Million USD | 120.179% |
| Harrow Health, Inc. | 9.72 Million USD | 252.494% |
| Biofrontera Inc. | -18.45 Million USD | 19.65% |
| DURECT Corporation | -24.68 Million USD | 39.933% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 115.089% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 113.563% |
| OptiNose, Inc. | -15.55 Million USD | 4.668% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 156.449% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 1354.399% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -1985.813% |
| SIGA Technologies, Inc. | 84.15 Million USD | 117.618% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 1925.985% |
| Shineco, Inc. | -26.55 Million USD | 44.163% |
| Phibro Animal Health Corporation | 84.6 Million USD | 117.525% |
| Procaps Group S.A. | 104.02 Million USD | 114.253% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -76.491% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -309.854% |
| Viatris Inc. | 3.51 Billion USD | 100.422% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -287.693% |
| Rockwell Medical, Inc. | -4.69 Million USD | -215.871% |
| Incannex Healthcare Limited | -18.5 Million USD | 19.871% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -1365.119% |
| Tilray Brands, Inc. | -72.84 Million USD | 79.645% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 104.809% |
| PetIQ, Inc. | 81.48 Million USD | 118.196% |
| Silver Spike Investment Corp. | 7.34 Million USD | 302.0% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 103.563% |
| Journey Medical Corporation | 1.92 Million USD | 871.838% |
| Alimera Sciences, Inc. | 7.27 Million USD | 303.78% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -252.029% |
| Assertio Holdings, Inc. | -222.44 Million USD | 93.335% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -271.544% |
| Embecta Corp. | 245.4 Million USD | 106.042% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 25.979% |
| Procaps Group, S.A. | 104.02 Million USD | 114.253% |
| PainReform Ltd. | -9.56 Million USD | -54.948% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 90.057% |
| Hempacco Co., Inc. | -12.77 Million USD | -16.078% |
| Talphera, Inc. | -9.84 Million USD | -50.65% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 109.102% |
| Alvotech | -484.86 Million USD | 96.942% |
| Lantheus Holdings, Inc. | 491 Million USD | 103.02% |
| Kamada Ltd. | 21.53 Million USD | 168.854% |
| Indivior PLC | 66 Million USD | 122.465% |
| Currenc Group, Inc. | -1.9 Million USD | -680.133% |
| Evoke Pharma, Inc. | -7.29 Million USD | -103.324% |
| Flora Growth Corp. | -45.87 Million USD | 67.676% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 25.979% |
| Evolus, Inc. | -41.81 Million USD | 64.537% |
| HUTCHMED (China) Limited | 25.52 Million USD | 158.081% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 106.14% |
| Akanda Corp. | -27.73 Million USD | 46.542% |